Synovial Fibroblast 3.2: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis-diagnosed donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 2 of 2) - Dataset (ID:20235)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
RA2159 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 4 | IFN-g | 53.0 | 82 | |
RA2159 | Poly(I:C) | 2 | ug/mL | 4 | IFN-g | 70.0 | 67 | ||||
N2645 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 4 | IFN-g | 40.0 | 72 | |
N2645 | Poly(I:C) | 2 | ug/mL | 4 | IFN-g | 73.0 | 80 | ||||
RA2708 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 4 | IFN-g | 82.5 | 36 | |
RA2708 | Poly(I:C) | 2 | ug/mL | 4 | IFN-g | 61.0 | 49 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | IFN-g | 29.0 | 85 | |
RA2159 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | IFN-g | 34.0 | 67 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | IFN-g | 22.0 | 76 | |
N2645 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | IFN-g | 27.0 | 61 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | IFN-g | 22.0 | 72 | |
RA2708 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | IFN-g | 39.5 | 76 | |
RA2159 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | IFN-g | 93.0 | 70 | |
RA2159 | IL-1 alpha | 100 | ng/mL | 4 | IFN-g | 88.0 | 82 | ||||
N2645 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | IFN-g | 56.0 | 58 | |
N2645 | IL-1 alpha | 100 | ng/mL | 4 | IFN-g | 66.5 | 70 | ||||
RA2708 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | IFN-g | 90.0 | 59 | |
RA2708 | IL-1 alpha | 100 | ng/mL | 4 | IFN-g | 87.0 | 89 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | IFN-g | 125.0 | 77 | |
RA2159 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 4 | IFN-g | 121.0 | 71 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | IFN-g | 107.0 | 73 | |
N2645 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 4 | IFN-g | 109.0 | 60 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | IFN-g | 124.0 | 81 | |
RA2708 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 4 | IFN-g | 113.5 | 76 | |
RA2159 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 4 | IFN-g | 114.0 | 75 |